# The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

> **NCT00108823** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 550 (—)

## Conditions studied

- Chronic Obstructive Pulmonary Disease, COPD

## Interventions

- **DRUG:** Roflumilast

## Key facts

- **NCT ID:** NCT00108823
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 550 (—)
- **Last updated:** 2016-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00108823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00108823, "The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00108823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*